Tribune News Service
New Delhi, January 22
A top medical journal today published safety and immunogenicity results of Covaxin’s Phase-I trials with the Phase-III trials about to be concluded.
Haryana health worker dies week after jab
Gurugram: A 56-year-old health worker vaccinated on January 16 died here on Friday, triggering panic among frontline warriors of the district undergoing immunisation. Sources said Rajwanti worked at the Bhangrola primary health centre. Her family blamed Covid immunisation for the sudden death. The authorities concerned have ordered a post-mortem examination.
Read full story:
The Lancet publication reports interim findings from the Phase-I clinical trial of India’s first indigenous Covid vaccine Covaxin. The results show it was well tolerated in all dose groups with no vaccine-related serious adverse events.
Cell-mediated responses were observed in the recipients. The most common adverse event was pain at the injection spot, followed by headache, fatigue and fever. The overall incidence of solicited local and systemic adverse events in this study was 14 to 21 per cent in all vaccine-treated groups, which is noticeably lower than the rates for some Sars-CoV-2 vaccine platform candidates and similar to the rates for some other inactivated Sars-CoV-2 vaccine candidates. One serious adverse event was found in an individual who received the 6 micro gram dose, but the same was not related to vaccination.